Robert Berkowitz, MD
Advanced Heart Failure and Transplant Cardiology · Hackensack, NJNPI 1437217973
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $502 of the $602 with a category attached, or 83.4%. 7 manufacturers reported payments, led by Abiomed at 36.0% of the total. Reporting peaked in 2019 at $171 and has fallen 89.4% since, to $18 in 2024. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in NJ, where the typical reported total is $7,482.
Across 13 payments — averaging $46.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$217
- Abbott$205
- Actelion Pharmaceuticals US, Inc.$100
- Boston Scientific$35
- Heartflow, Inc.$18
- Amarin Pharma, Inc.$15
- plus $12 from 1 others
Across 1 payment — averaging $210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$210
What the payments were for
- Food & beverage$50283%
- Education$10017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 4 | $217 |
| Abbott | 4 | $205 |
| Actelion Pharmaceuticals US, Inc. | 1 | $100 |
| Boston Scientific | 1 | $35 |
| Heartflow, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$120
How this compares
$602 in reported general payments places this provider in the 0th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
See all advanced heart failure and transplant cardiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevatioSildenafil Citrate | 13 | $289,023 |
| EliquisApixaban | 142 | $156,548 |
| EntrestoSacubitril/Valsartan | 69 | $94,042 |
| Bosentan | 23 | $43,928 |
| JardianceEmpagliflozin | 16 | $26,032 |
| CorlanorIvabradine Hcl | 18 | $20,086 |
| XareltoRivaroxaban | 15 | $18,430 |
| Bisoprolol Fumarate | 103 | $4,502 |
| Eplerenone | 45 | $4,304 |
| Rosuvastatin Calcium | 157 | $4,175 |
| Metoprolol Succinate | 146 | $3,282 |
| Sildenafil Citrate | 22 | $2,640 |
| Candesartan Cilexetil | 24 | $2,598 |
| Amiodarone Hcl | 81 | $2,101 |
| Midodrine Hcl | 28 | $1,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Bosentan | $100 | $43,92823 claims |
| Johnson & JohnsonXarelto | $12 | $18,43015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
Other advanced heart failure and transplant cardiology in Hackensack
- Kanika ModyHackensack$107K
- Kumar SatyaHackensack$3K
- David SilberHackensack$3K
- Bernard KimHackensack$949
- Abhishek SinghMorristown$283K
- Kulpreet BarnBarnegat$92K
- Robert MohapatraSewell$84K
- Saad AhmadMorristown$74K
- Mark ZuckerMorristown$44K
- Saurabh KapoorEnglewood$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.